Of note, the MOv18 IgE specific for the folate receptor alpha (FRα) was demonstrated to have anti-tumor effects in vitro and in vivo and is in phase 1 clinical trials testing with early data demonstrating demonstrated safety and efficacy in ovarian cancer patients (64). Here, FOLR1 is linked to ovarian carcinoma.